Succeeding in Heart Failure, Incrementally
This article was originally published in Start Up
Executive Summary
Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
You may also be interested in...
Berlin Heart: Starting Over
After cutting his teeth on heart pump technology at re-start Impella, Rolf Kaese thought he had found the perfect vehicle to build a ventricular assist device business at Berlin Heart. But now Kaese is starting over and so is Berlin Heart after a falling out between the two, in a tale that's an object lesson to anyone who's ever had to begin again.
NovaCardia Inc.
For many heart failure patients, diuretics are self-defeating; they activate a fluid-conservation mechanism that both limits drugs' effectiveness and damages kidneys. So great is the need for kidney-preserving diuretics that when a partner at Domain Associates learned of a promising drug candidate, he founded NovaCardia to develop it.
CoGenesys Inc.
CoGenesys has licensed rights to albumin fusion proteins that improve the bioavailability of proteins better than other methods such as PEGylation, its founders believe. The start-up's pipeline presently contains a version of BNP for treating heart failure.